<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The availability of several definitions of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> has created potential <z:hpo ids='HP_0001289'>confusion</z:hpo> concerning its prognostic utility </plain></SENT>
<SENT sid="1" pm="."><plain>At present, little data exist about the risk factors associated with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in diabetic patients </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To identify risk factors associated with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> according to three diagnostic criteria: World Health Organization (WHO), Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults - Adult Treatment Panel III (NCEP-ATP III), and International <z:mp ids='MP_0002055'>Diabetes</z:mp> Federation (IDF) </plain></SENT>
<SENT sid="3" pm="."><plain>SUBJECTS AND METHODS: A logistic regression model was used to identify demographic, clinical, and lifestyle variables related with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (N = 1259) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000822'>Hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (HbA(1c)) â‰¥7% were associated with increased risk of WHO-defined <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (odds ratio [OR], 2.33; 95% confidence interval [CI]: 1.60-3.40; OR, 1.79 95% CI: 1.25-2.55; and OR, 1.58; 95% CI: 1.12-2.22, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>The risk of presenting <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> according to NCEP-ATP III criteria was increased in female patients (OR, 2.02; 95% CI: 1.37-2.97), elevated fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> levels (OR, 5.99; 95% CI: 3.56-10.07), <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (OR, 2.28; 95% CI: 1.57-3.32), <z:hpo ids='HP_0000822'>hypertension</z:hpo> (OR, 2.36; 95% CI: 1.59-3.53), and <z:chebi fb="32" ids="24621">endocrine</z:chebi> disorders (OR, 1.64; 95% CI: 1.06-2.57) </plain></SENT>
<SENT sid="6" pm="."><plain>For the IDF criteria, female patients and patients with <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> or insulin treatment were at higher risk of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (OR, 4.00; 95% CI: 2.35-6.80; OR, 2.72 95% CI: 1.22-6.04; and OR, 1.96 95% CI: 1.24-3.11, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The risk factors for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> patients are highly dependent on the criteria used to define the syndrome, supporting the need for a single clinically useful and epidemiologically useful definition </plain></SENT>
</text></document>